In recent legal news, the Federal Circuit’s interpretation and application of the Supreme Court’s recent enablement decision in Amgen v. Sanofi has had significant implications, particularly noticeable in the case of Baxalta v. Genentech. This evolving circumstance has resulted in an increasing number of antibody claims undergoing critical scrutiny under the “post-Amgen” environment.
The second half of September only witnessed two precedential IP decisions from the Federal Circuit, which were notably thin on the ground for blogging content. One such judgement was that of Baxalta v. Genentech (2022-1461). This key decision was drafted by Chief Judge Kimberly Moore with the concurrence of Judges Raymond Clevenger and Raymond Chen, marking a key shift in evaluating antibody claims.
As reported by Bradley Arant Boult Cummings LLP, the court’s decision provides a comprehensive insight into how it interpreted and applied the Supreme Court’s recent enablement decision. Without a doubt, the landscape of legal rulings pertaining to antibodies is changing, and professionals within the sector must adapt to this transformed dynamic.
Further documentation and analysis of these recent decisions will undoubtedly reveal more about the impact and future interpretations of the Amgen v. Sanofi ruling. This case and the resultant enablement decision are reshaping the way legal professionals view and handle antibody claims, effectively marking a new era in this specific area of IP law.